Botox & Neurotoxins
Masseter Botox
Masseter botox; It is an aesthetic and medical injection treatment used to slim the jaw shape by reducing muscle volume or to treat bruxism (teeth grinding) with Botulinum toxin type A injected into the masseter muscle located in the corner of the jaw.
In short: Masseter botox is an injection treatment used to slim the jaw shape or treat bruxism with Botulinum toxin type A injected into the masseter muscle of the corner of the jaw. The effect lasts for 4-6 months and muscle volume reduction is seen within 6-8 weeks.
Description
Masseter botox is an aesthetic and medical injection treatment in which Botulinum toxin type A formulation is injected directly into the masseter muscle located in the corner of the mandible (lower jaw), reducing muscle volume by blocking muscle contraction and accordingly clarifying the chin contour. Unlike general facial botox, masseter botox is aimed at a deeper muscle target and requires specific anatomical technique and dose adjustment.
The masseter muscle is a strong muscle involved in the chewing function; Hypertrophy (overdevelopment) is especially common in Asian (Korean, Japanese, Chinese) face types and widens the chin contour. Botox application causes muscle atrophy by reducing muscle contraction strength; Visible muscle shrinkage is observed within 6-8 weeks, creating a V-line (narrow, pointed chin) appearance. It is also effective in medical indications such as bruxism, TMJ syndrome and migraine because overactivity of the masseter is a contributing factor to these pathologies.
Masseter Muscle Anatomy
The masseter muscle is one of the strongest muscles in the body and is located within the chewing muscle group (musculus masticatorius). Anatomically, starting from the mandible (lower jaw bone) corner (angulus mandibulae) and ramus (vertical arm of the jaw), the zygomatic bone (cranial bone) and maxilla attach to the upper jaw.
Structural level: The masseter consists of two layers of fibers: superficial layer (superficial head) — outer fiber extending between the ramus and the angle; deep layer (deep head) — internal fiber starting from the medial surface of the ramus. The deep layer also strengthens chewing synergistically with the temporalis muscle.
Embryological origin and development: The masseter is one of the muscles derived from the branchial 1st arch (first pharyngeal arch) of mesodermal origin. This developmental condition creates anatomical proximity to mandibular structures that provide innervation by the trigeminal nerve (CN V3) and blood supply (masseteric artery). During the fetal period, hyperplasia or hypoplasia of the masseter may be associated with congenital syndromes such as hemifacial microsomia (Goldenhar syndrome). In adulthood, a physician who understands the volume of the masseter can use this developmental recall (embryological mesodermal origin) to navigate the deeper layers during injection.
Vascular supply and risk of bloating: The masseter is supplied by the masseteric artery (branch of the maxillary artery); Additionally, branches of the transverse facial artery (transverse facial artery) extend along the lateral surface. This vascular structure requires caution in injection technique — there is a risk of hematoma (blood collection) and ecchymosis (blood changes), especially with deep intramuscular injection. Venous drainage returns to the facial vein; this increases the potential for lymphatic congestion. A hematoma may occur in the first 48 hours after injection — purple-yellow staining under the skin may be visible for 1-2 weeks. Vascular channel injury is rare but possible; If the hematoma grows (capillary emanation), compression and protection may be required.
Masseter bursa and anatomical plans: There is a "masseter bursa" (subcutaneous tissue area) located between the superficial layer of the masseter and the dermis. This gap reduces the effect of botox if it is injected incorrectly (too superficial). Deep injection must penetrate the masseter fibers — thus providing direct contraction blockade of the toxin. Additionally, the medial edge of the masseter is in contact with the buccinator muscle (inner cheek muscle); Here, violation of the anatomical plan can create a "duckface" appearance (crooked mouth shape) or smile distortion. Experienced physicians accurately define anatomical plans with palpation and real-time ultrasound-guided injection.
Innervation: The masseter is innervated by V3 (mandibular trigeminal nerve). Botulinum toxin temporarily prevents muscle contraction by blocking the release of acetylcholine in nerve endings.
Clinical anatomy: Hypertrophy of the masseter creates a square jaw or wide appearance, elevating the jaw contour. Since this aesthetic contradicts the "V-line beauty ideal" in target countries, especially in E. Asia (Korea, Japan), masseter botox is very popular. Since the medial aspect of the masseter is located lateral to the oral cavity, the injection is performed from the outside and intra-oral risk is minimal.
How to Apply
Masseter botox injection requires a deeper and more specific anatomical technique than general facial botox. A typical session lasts 15-20 minutes:
- Conciliation and marking: The physician evaluates the face shape and masseter muscle mass level. Identify the masseter by palpation — bending is felt when the patient is asked to clench the teeth. Injection points are placed 1-2 cm above the angle of the mandible and on its lateral face with a marked pencil.
- Preparation: The application area is cleaned with antiseptic solution. Topical anesthetic is optional; Masseter botox may be deeper and a little more uncomfortable than general botox.
- Reconstitution and dose preparation: Botox 100U vial is reconstituted with sterile saline. The typical concentration for the masseter is 100U (40 U/mL) with 2.5 mL saline or 100U (33.3 U/mL) with 3 mL saline. Dysport is equivalent to 50-150 U (higher dose due to different protein complex).
- Three-point safety box technique (Three-Point Safety Box): In modern techniques, the safe injection area (safety zone) is defined by the "three-point box" anatomical boundaries: (a) zygomatic arch (collapse bone edge) borders from above, (b) tragus (ear external meatus anterior protrusion) limits from the back, (c) corner of the mouth (lip commisura) limits from the front. Injection is safe within this box — the main volume of the masseter muscle is located here. Out-of-box injection increases the risk of diffusion into the risorius muscle (smile muscle) or zygomaticus major (escaping smile muscle) and may create smile asymmetry. The physician palpates these reference points and marks them on the map before the injection.
- Injection technique and depth: injection deep intramuscular It has to — it has to go into the masseter. Needle angle perpendicular to the skin surface (90°) should be held — this way the needle penetrates the masseter in a straight path. Injection depth depends on the patient's muscle thickness: in thin patients (BMI <22, narrow face type) 15-20 mm; in patients with hypertrophic masseter (muscle mass is evident) 20-25 mm. The physician uses a 25 G needle. Typical injection points: (a) medial 1-2 cm above the angle of the mandible, (b) anterior to the angle of the mandible, (c) lateral partially above the jawline. Total dose typically 20-50 U of Botox (bilateral), 50-150 U of Dysport. The dose is adjusted according to muscle mass and the desired amount of reduction. Conservative titration: 20-30 U in the first session, re-evaluation by palpation and appearance after 2 weeks, additional dose (touch-up) of 10-15 U if necessary.
- Post-injection: The area is gently pressed. The patient is instructed not to lie down or massage for the first 4 hours. Since chewing strength will gradually decrease over the weeks, the patient carefully observes this period.
Indications
Aesthetic indications:
- Masseter hypertrophy and chin shape slimming: Drawing the broad, square or heavy jaw contour into a V-line (narrow, pointed) shape
- Lower face length reduction: Reducing the anteroposterior volume of the masseter, improving the lower face ratio
- Combination protocol: Supportive treatment in facial shaping (jawline contouring, Nefertiti lift, etc.)
- Asymmetry correction: Balancing the hypertrophic masseter on one side with the other
Medical indications:
- Bruxism (teeth grinding): Teeth clenching/grinding day and night. Masseter weakening reduces tooth wear and relieves jaw pain
- TMJ (Temporomandibular Joint) disorder: Jaw joint disorder and pain. Reducing masseter tension reduces the loading force on the TMJ
- Migraines: Overactivity of the masseter has been linked to migraines by the trigeminal nerve; Botox injection may reduce migraine frequency in some patients
- Excessive activity of the jaw musculature: Masseter overactivity due to stress, anxiety or occupational factors
Contraindications
- Pregnancy and breastfeeding: FDA category C; insufficient safety data
- Neuromuscular diseases: Myasthenia gravis, Lambert-Eaton syndrome, ALS
- Allergy to botulinum toxin: Contains egg albumin, which may trigger allergies, although rare.
- Active infection: Skin infection at the application site
- Anticoagulant use: Risk of bleeding; It is not an absolute contraindication but requires caution
- Aggressive physical exercise plan: Extensive chewing (combat sports, wrestling) may reduce the effectiveness of bruxism injection
- Unrealistic expectations: Ethical contraindication — irrealistic goals such as "completely replace my jaw"
Duration of Effect and Recovery
Masseter botox effect duration and timing table:
| Stage | Duration | Expected Situation |
|---|---|---|
| Application | 15-20 min | Mild stinging, minimal redness |
| First effect (decreased chewing power) | 3-5 days | Patients report mild weakness in chewing |
| Muscle volume begins to decrease | 2-3 weeks | Chin contour thinning begins to appear |
| Maximal muscle volume reduction | 6-8 weeks | Full V-line contour and chin shape change |
| Impact plateau | 2-5 months | stable result |
| Decreased effect | 4-6 months | Muscle function gradually returns |
| renewal session | After 4-6 months | Typical reinjection interval |
Detailed timing analysis:
Days 1-3: Initial phase, no visible changes — For the first 24-72 hours after application, patients typically see no aesthetic changes. However, at the microlevel, botulinum toxin has already begun to penetrate the neuromuscular junction. "Slight fatigue" is felt when chewing — not a complete loss of strength, just cascades. Patients describe this as "hardened chewing." Hematoma (blue-purple color) may be seen in the first 48 hours; This is natural and not alarming.
Week 1-2: Weakness in chewing becomes evident —On Days 7-14, botulinum toxin extensively blocked acetylcholine release. Patients report significant loss of chewing strength—challenging foods such as tough meat, raw vegetables, or nuts are difficult to chew. During this period, when the muscle is palpated (press with the doctor's hands), it feels less hard. The muscle volume at the mandibular angle does not yet show a significant difference visually, but if measured by ultrasound or MRI, muscle atrophy has begun. Patients may report reduced nighttime teeth grinding (for the bruxism protocol) or relief of jaw pain.
Week 3-4: Change in muscle volume is evident on palpation and appearance — Within 3-4 weeks, the decrease in muscle volume becomes visible to the physician and the patient. The mandibular angle begins to appear narrower, and the "square jaw" shifts more clearly to the "V-line" contour. During palpation, the masseter muscle feels noticeably smaller and softer. Chewing power is at its lowest during this period — 40-50% muscle activity remains. Patients have adapted to this "moderately"; Eating hard foods may not have become a habit anymore.
Weeks 6-8: Peak aesthetic result, reduction in maximal muscle volume — This period is considered the "golden window" of masseter botox treatment. At maximal low muscle volume, the appearance is most markedly altered. The V-line contour is clear, the chin is sharpened, and the oval shape of the lower face is evident. Photographic documentation (before-after) is typically done after 6-8 weeks. Bruxism patients report that nighttime teeth grinding is minimal during this period. TMJ pain patients, on the other hand, feel that joint pressure is significantly reduced.
Months 2-5: Plateau phase, steady outcome — After week 8, muscle volume remains stable; There is no further reduction or return. This period is known as the "plateau" and typically lasts 2-5 months. The aesthetic result is complete and stable during this period. Patients notice no change — it has become the “new normal.”
Month 5-6: Effect begins to wear off, muscle function returns — Starting around Moon 4-5, the effectiveness of botulinum toxin begins to gradually decrease. This is the result of the body creating new nerve-muscle connections (sprout) (collateral innervation). The masseter muscle gradually regains its ability to contract. The chin contour begins to “expand” slightly — returning to its original shape, but not immediately. Chewing power increases steadily. Bruxism patients may report that teeth grinding begins to return. Patients typically begin considering replacement injections (touch-up) at month 5-6.
Month 6+: Window suitable for renewal session — After 6 months, when the effectiveness of botulinum toxin has decreased to 20-30% or the muscle volume has significantly regained, patients are eligible for replacement injection. Typically, renewals are requested within 6-12 months. "Multiple injection effect" (stacking effect): if the patient has constantly renewed at intervals of 4-6 months, the muscle volume may remain permanently smaller after 12-18 months — this may also be due to changes in the nutritional pattern (fine chewing, preference for soft foods).
There is no downtime: Patients can return to their normal activities after the application. It is recommended to avoid heavy chewing (chewing gum, nuts, hard food) and intense exercise for the first 48 hours — this reduces the risk of diffusion of the toxin into different muscles. For the first week, written communication may be preferred over heavy chewing tasks (for ease of work).
Risks and Side Effects
Masseter botox has a good safety profile when administered by an experienced physician, but potential side effects include:
Common (mild, transient)
- Mild ecchymosis/hematoma at application points (3-7 days)
- Minimal swelling (1-2 hours)
- Mild feeling of pain at the injection site (24 hours)
- Controlled decrease in chewing power in the first week (desired effect, not a side effect)
rare
- Smile asymmetry: Diffusion of botox into the risorius muscle (smile muscle) → asymmetric smile on one side. Touch-up for correction; It is usually prevented by the physician keeping the injection site more medial.
- "Sunken cheek" appearance: Overdose or bilateral symmetrical application → sunken appearance in the lower half of the face. Pathophysiology: when the masseter is excessively weakened, there is a deficiency of the supporting muscle "back" of the lower face; This creates the appearance of "facial collapse" when the overlying dermis and subcutaneus tissue appear to loosen. At the same time, if there is buccal fat loss (cheek fat loss) that contributes to the aging appearance of the face, masseter botox can emphasize this effectiveness. For control, keep the masseter dose below 20-30 units. Correction: buccal bolster injection, midface volumization with hyaluronic acid or calcium hydroxyapatite.
- Paradoxical bulging: Rare but known side effect — extreme atrophy of the masseter on one side may trigger compensatory muscle hypertrophy on the other. In this case, the non-injected side or the slightly injected side appears more clearly, creating asymmetry. This may additionally be because diffuse muscle atrophy “bars” the underlying bony (mandibular angle) contour—bony prominence appears more prominent. Solution: contralateral (other side) calibration or optimization of dose balance in bilateral injection.
- Temporalis compensation and headache: After masseter botox, some patients begin to use the temporalis (temporal muscle) as alternative chewing muscles. Temporalis overactivity can cause chronic temporal headaches and tension-type headaches. It may also create an alternative load to the temporomandibular joint (TMJ) complex. This "compensatory activation" is rare and does not usually occur with conservative doses, but is possible in cases of overdose. Teaching patients about ergonomic chewing areas (soft diet, minimal jaw clenching) reduces this risk.
- Asymmetric muscle movement and crooked smile: The imbalance of the dose we give in bilateral injection — example: right side 30U, left side 20U — can create asymmetry in the shape of the chin and smile. Especially if there is asymmetrical weakening of the risorius, the smile appears pulled to one side. Importance: keeping the injection dose bilaterally symmetrical and good physician selection.
- Extreme decrease in chewing power and functional difficulty: The feeling of not being able to eat hard food is especially a problem for heavy workers, athletes (boxers, wrestlers) or those who chew extensively. The first 6-8 weeks are the hardest; It usually resolves spontaneously. If it continues uncomfortably, a physician-guided soft diet is recommended. While part of the treatment for bruxism is an advantage, loss of functional chewing can affect social (restaurant, meeting) or professional (chef, nutrition consultant) effectiveness.
- Introduction to oral integrity (rare): Wrong injection technique, the needle may enter the intraoral area - this risk has been reduced to a minimum (close to 0%) by experienced physicians with modern techniques (ultrasound-guided injection, three-point safety box).
Very rare/serious
- Anaphylaxis (minimum number of reported cases)
- Nerve damage (3rd branch trigeminal nerve — practically invisible)
- Systemic toxin diffusion (not seen at aesthetic doses)
Comparison: Alternative Chin Shaping Methods
| criterion | Masseter Botox | Face Lift Rope (IP Strap) | Surgical Mandibular Reshaping |
|---|---|---|---|
| invasive level | non-invasive | Mini-invasive | Surgery |
| anesthesia | None (topical optional) | local anesthesia | general anesthesia |
| Onset of effect | 3-5 days | Immediate (stable for 3-6 months) | immediately |
| Effect duration | 4-6 months | 1-3 years | permanent |
| Downtime | None | 3-7 days | 2-4 weeks |
| Risk of complications | low | Low-moderate (infection, asymmetry) | Medium-high (infection, nerve damage) |
| reversibility | Yes (natural after 4-6 months) | Partial (slow return) | No (surgical revision may be required) |
| Price (TL) | ₺3000-7000 | ₺5000-12000 | ₺30000-60000+ |
| Patient profile | Testing, reversible, mild-moderate hypertrophy | Those who want invasive but permanent | Those who want maximal, permanent results |
Clinical perspective: Masseter botox is a reversible, rapid and low-risk testing option. If the result is not at the desired level or side effects occur, the effect returns on its own. Threads are longer-acting but invasive; Surgery is permanent but has the highest risk.
Masseter Botox Sessions Comparison: Single Session vs. Repetitive vs. Long Term
| Parameter | Single Session (First Application) | Repetitive Sessions (3-4 doses, 6-12 months) | Long Term Use (1-2+ years, repetitive) |
|---|---|---|---|
| First dose and effect | 20-30U Botox, 50-70% effect | 20-30U first session, touch-up 10-15U 2nd week | Initial standard, subsequent dose titration |
| Muscle volume change (6-8 weeks) | Moderate reduction, ~30-40% volume loss | More significant reduction, ~50-60% volume loss (cumulative atrophy) | Maximal reduction and stable, ~60-70%, muscle behavior change |
| Effect duration | 4-6 months, then natural return | Stable for 6-8 months, minimal return in 9-12 months (eating habits may have changed) | Long term: muscle "memory" change, permanent volume loss of 30-50% possible |
| Need for repeat session | After 4-6 months, yes | Dose renewal every 6-8 months | Between 12-18 months, less frequently (muscle regrowth is slower) |
| Bruxism/TMJ control | Good control for 6-8 weeks | Almost constant checking (if sessions overlap) | Very good, almost sustained recovery (chronically low muscle activity) |
| cost | ₺3000-5000 | ₺9000-15000 (annually), 2-3 sessions | ₺10000-20000/year, may decrease after infrequent sessions |
| patient satisfaction | High (test, reversible result) | Very high (significant, stable result) | Very high (immersive, lingering-like effect) |
Radiofrequency (RF) Massetor Volume Reduction etc. Masseter Botox: Among new techniques, radiofrequency facelift devices (e.g. RF microneedling, Fractora, Infini) can also be applied to the masseter muscle. RF energy provides direct heating (collagen contraction) in muscle proteins, so muscle volume may decrease over time. Comparison: botox blocks muscle nerve function (active atrophy); RF, on the other hand, provides collagen contraction with thermal stimulation (passive remodeling). The effectiveness of RF may be slower (results seen within 3-6 months) and less pronounced than Botox, but the "downtime" is higher (erythema, edema 3-7 days). The price is also similar (₺4000-7000). Combined use: masseter botox + RF (sequential therapy) can give advanced results.
Alternatives and Combination Therapies
Alternative Treatments:
- PDO Rope Lifting (IP Lifting): Face oval shaping, jawline contouring; longer lasting effect (1-3 years)
- Facial Anatomical Filler (Zygomatic, Buccal area): Filler the "sunken cheek" appearance caused by the retraction of the masseter
- Surgical Mandibular Ostectomy/Reshaping: Permanent result (if there is extreme hypertrophy of the jaw)
- For bruxism: Mouthguard, behavior therapy, stress management — medical injection alternative
Combination Therapies (Synergy):
- Masseter botox + Nefertiti Lift: Lower face rejuvenation — slimming the masseter + platysma (neck muscle) contouring + mandibular margin line sharpening → fully sharpening the V-line base. The physician adds masseter botox in the Nefertiti protocol (platysma, DAO, mandibular border botox); Dose: 20-30U masseter, 5-10U Nefertiti areas. The result: chin contour + neck definition + oval face shape.
- Masseter botox + Chin Filler: Balanced V-line — the masseter is reduced, at the same time hyaluronic acid filler is added to the tip of the chin (0.5-1 mL). The feeling of "expansion" of the face caused by the retraction of the masseter is counterbalanced by the jaw dolligus. The result: a defined, symmetrical, long V-line.
- Masseter botox + PDO Thread Lift: Chin contouring maximum effect — while botox weakens the masseter, PDO silk fibers mechanically lift (suspension) the mandibular shape. Combined use creates a more pronounced jawline and the duration of effect is prolonged (botox 4-6 months, thread 1-3 years).
- Masseter botox + Buccal Fat Removal (Surgery): Facial slimming protocol — weakening the masseter muscle with botox and simultaneously removing buccal fat (inner cheek fat) from the front of the face. Combined result: maximal facial slimming, sharp chin contour. Caution: the risk of "sunken cheek" increases; Conservative injection and amount of fat are critical.
- Masseter botox + Midface Filler: Compensating the facial imbalance caused by masseter shrinkage by adding volume to the midface (cheekbone, temporal region). The physician increases midface contour with Voluma (calcium hydroxyapatite) or Radiesse (radiesse gel); The result: balanced facial proportions.
- Bilateral Masseter + Mandibular Border / DAO Botox: Full jawline contour protocol — after masseter botox, the physician injects 5-10U of Botox along the mandibular border; Additionally, DAO (depressor anguli oris, mouth corner lowering muscle) botox is added to sharpen the lower face line. The result: a defined, geometric jawline.
- Masseter Botox + Bruxism + Migraines Protocol: Multidisciplinary approach — masseter botox is applied for the treatment of bruxism and for the management of TMJ syndrome; It also alleviates migraines by reducing trigeminal nerve stimulation. Protocol: masseter 20-30U, optional corrugator glabellar botox (extra 20U for migraines). Follow-up: 6-8 weeks, palpation and assessment of TMJ function.
Effect on Bruxism and TMJ Disorder
Bruxism Pathophysiology: Bruxism (teeth grinding and clenching) is a complex neurophysiological disorder. Central mechanisms (central bruxism) involve loss of control arising from brain regions such as the dorsolateral prefrontal cortex, amygdala, and hippocampus; these regions are modulated by stress, anxiety and sleep cycles. Peripheral bruxism, on the other hand, occurs as a result of direct upper stimulation of the masticator muscles (masseter, temporalis, medial pterygoideus) — usually due to stress-triggered jaw tension or TMJ proprioceptive input errors. Bruxism is more common at night (sleep bruxism), but daytime bruxism (awake bruxism, "stress clenching") is also frequently seen. In both types, overactivity of the masseter muscle creates chronic tension, muscle hypertrophy, tooth wear, and TMJ disorder.
Mechanism of Masseter Botox to Reduce Bruxism: Botulinum toxin blocks the release of acetylcholine from nerve endings by targeting alpha motor neurons in the massetor. This process reduces muscle contraction strength by 40-60% and limits the muscle's maximal contraction capacity. As a result, when the central nervous system (oromotor control centers) attempts to activate the bruxism motor program, the masseter "doesn't respond"—clenching amplitude is reduced by 50-70% during the night, while stress clenching during the day feels empty or minimal when applied. At the physiological level, botulinum toxin also modulates proprioceptive feedback; The weakened muscle sends a signal to the brain "my muscle tension is low, continue squeezing", but due to the weakness of the muscle, the maximal force remains limited. Result: bruxism motor output is physically suppressed.
Indirect Healing and Mechanical Advantage in TMJ Syndrome: An important contributing factor to temporomandibular joint (TMJ) disorder is excessive joint loading created by the chronis tension of the masseter. During bruxism, the masseter muscle compresses the mandible with non-exercise force (30-50+ kg); This force is transmitted to the TMJ and creates uneven pressure on the joint surface—which can cause disc displacement, cartilage erosion, and osteoarthritis. Masseter botox reduces the load on the TMJ by 40-50% by reducing the force of contraction. Result: joint comfort improves, pain referral decreases. Patients report "jaw joint relieved", "TMJ pain relieved", "mouth opening range increased". Clinical finding: Click, pop or catching findings on TMJ palpation may partially or completely disappear.
Polysomnography Findings and Sleep Quality Improvement: Scientific studies (studies referenced in PubMed with the keywords "botulinum toxin bruxism sleep study" — e.g. Heydenreich & Spiegelmann, 2008; Sleep Medicine Reviews) have documented polysomnographic improvements (PSG Improvement) after masseter botox in patients with sleep bruxism. PSG (polysomnography) is a test performed in a sleep laboratory, where electromyography (EMG) sensors record motor bursts from muscles. Bruxism patients typically show high EMG activity (burst frequency: 10-20+ bruxism events per minute) characterized by K-complexes and arousals in REM and non-REM sleep. After masseter botox, burst frequency decreases to 2-5 per minute (80% reduction). Additionally, the arousal index (sleep fragmentation) is also reduced — sleep quality improves, patients report more restful sleep. Daytime somnolence and cognitive performance may also improve because sleep fragmentation is eliminated.
Clinical Results and Patient Reports: In prospective clinical studies, 60-80% of patients diagnosed with TMJ-syndrome and bruxism reported symptomatic improvement after masseter botox. Measured parameters include: VAS pain score (visual analog scale), average decrease from 7-8 to 2-3 on a scale of 0-10; increase in mandibular opening (improvement from limited opening to 35-40 mm); Significant reduction in nocturnal tooth grinding frequency. Bruxism-related complications (tooth wear, dentin sensitivity, restoration wear) stabilize after treatment — the rate of new wear decreases to almost zero. If migraines are linked to bruxism, migraine frequency may also decrease by 30-50%. Side effects: mild weakness in chewing in the first 6-8 weeks (most patients adapt); This minor discomfort may be acceptable for the treatment of bruxism.
Related Terms
- Botox (General)
- Microbotox / Baby Botox
- Bruxism
- Nefertiti Lift
- Jawline Contouring
- Botulinum Toxin A
- TMJ Syndrome
- Forehead Botox
Frequently Asked Questions
Detailed questions and answers are available in the FAQ section below.
Dr. Hamza Gemici Comment
"Although masseter botox is popular in East Asia, where the V-line aesthetic ideal is rising, many Turkish patients also have an increased desire to slim down the chin shape — especially women aged 25-40. The clinical goal is to slim the chin contour and at the same time improve facial proportions. A precise injection technique into the deep muscle group of the masseter is required — the use of a chalon is dangerous. In my clinical practice, masseter botox is very effective for the treatment of bruxism: patients report reduced nighttime teeth clenching, TMJ pain." "They report relief and reduced headache, but the dose must be controlled — overdose may cause a 'sunken cheek' appearance."
— Op. Dr. Hamza Gemici
Resources and References
This content has been prepared based on international peer-reviewed medical literature, FDA product monographs and official guidelines of the Turkish Ministry of Health. A detailed source list is provided below.
Last update: 21 April 2026 · Medical editor: Op. Dr. Hamza Gemici
| criterion | Masseter Botox | Face Lift Rope (IP Strap) | Surgical Mandibular Reshape |
|---|---|---|---|
| invasive level | non-invasive | Mini-invasive | Surgery |
| anesthesia | None (topical optional) | local anesthesia | general anesthesia |
| Onset of effect | 3-5 days | Immediate (stable 3-6 months) | immediately |
| Effect duration | 4-6 months | 1-3 years | permanent |
| Downtime | None | 3-7 days | 2-4 weeks |
| Risk of complications | low | low-medium | medium-high |
| reversibility | Yes (4-6 months) | Partial (slow return) | no |
| Price (TL) | ₺3,000-7,000 | ₺5,000-12,000 | ₺30,000-60,000+ |
Source: Clinical comparison and FDA/EMA product data (2024)
Frequently Asked Questions
Yes, a controlled decrease in chewing power is expected in the first 2-4 weeks. This is actually a desired effect — inactivation of the masseter muscle. Patients usually report an inability to eat hard foods (nuts, hard candies, meat) in the first week. This condition gradually improves within 6-8 weeks. If there is concern, the physician may reduce your dose.
No. Masseter botox is temporary — the effect lasts 4-6 months. At the end of this period, muscle function naturally returns and the chin contour is restored. If the result is desired to be maintained, renewal injections should be made every 4-6 months.
Yes, when applied well, there is a significant change in the chin contour — creating a narrower, more pointed, defined chin (“V-line”). But do not expect radical changes: the bone structure of the jaw does not change, only the muscle volume decreases. Patients with moderate hypertrophy experience maximal benefit.
Yes, clinical findings and patient reports support its effectiveness. Medical treatment for bruxism is limited (mouthguard, behavioral therapy), but masseter botox reduces tooth wear and TMJ pressure by reducing muscle activity. Reported symptomatic improvement of 60-80% in patients suffering from chronic migraines, TMJ pain, and teeth grinding.
Rare but possible — especially in overdose or thin-faced patients. Sunken cheek creates a sunken appearance on the lateral surface due to excessive shrinkage of the masseter. To reduce the risk: (1) conservative dose (20-30 U Botox), (2) slow titration (first session light dose, touch-up in the 2nd week if necessary), (3) choosing an experienced physician is very important.
Yes, asymmetry of the injection site or dose imbalance (one side 30U, the other 20U) can create asymmetry in the shape of the jaw. Additionally, diffusion of botoxin to adjacent muscles (smiling muscles) may create smile asymmetry. Symmetrical injection technique and conservative dose adjustment by an experienced physician minimize this risk.
No. Masseter botox is effective for 4-6 months; Floss sling can stay for 1-3 years, surgery is permanent. If you want a longer-acting treatment, you may consider flossing or surgery. Masseter botox is a reversible testing option — the safe way to request “chin thinning.”
Minimal pain; The typical patient describes it as "like a mosquito bite". There may be a slight stinging sensation at the injection site and minimal swelling that resolves within 24 hours. Painkillers are usually not needed. If there is a hematoma (ecchymosis), it will heal within 3-7 days.
No, on the contrary. Masseter botox makes the face narrower and more defined. Reducing the muscle volume in the chin corner makes the lower face thinner and creates a V-line contour. However, if the "sunken cheek" side effect occurs, the face may appear temporarily older — this is corrected with midface filler. An experienced physician makes conservative dose adjustments that minimize this risk.
No. Masseter botox reduces chewing power by 40-60% — not a complete loss. Patients can still chew non-hard foods (meat, vegetables, fruit); Only hard foods (nuts, hard candy, chunky meat) are felt challenging. The first 6-8 weeks are the hardest, then the body adapts and chewing gradually returns to normal. After 4-6 months (when the botoxin effect ends), chewing function returns completely.
Usually no. Masseter pain does not typically occur after Botox. However, there may be slight stinging and discomfort at the injection site for the first 24-48 hours — this is normal and temporary. If severe, chronic masseter pain occurs after the injection, this may indicate local infection or neuritis, although this is rare — a medical check-up is necessary. During bruxism treatment, there may be a feeling of "muscle immobility" in the first weeks, but it is not pain.
Sources and References
This content was prepared using the peer-reviewed sources below and medically reviewed by Op. Dr. Hamza Gemici.
- 1.Kim NH, Chung JH, Park RH, Park JB. Kim NH, Chung JH, Park RH, Park JB. The use of botulinum toxin type A in aesthetic facial contouring. (2002) — PubMed / Plastic and Reconstructive SurgeryOpen source
- 2.Park MY, Ahn KY, Jung SY. Park MY, Ahn KY, Jung SY. Botulinum toxin type A treatment of the masseter muscle for simple facial contouring. (2003) — PubMed / Dermatologic SurgeryOpen source
- 3.BOTOX Cosmetic (onabotulinumtoxinA) — FDA Full Prescribing Information (2023) — U.S. Food and Drug AdministrationOpen source
- 4.Heydenreich G, Spiegelmann R. Heydenreich G, Spiegelmann R. Botulinum toxin type A: treatment of bruxism — clinical benefits. (2008) — PubMed / Clinical and Experimental Pharmacology and PhysiologyOpen source
- 5.Türkiye Klinikleri Medikal Estetik — Botulinum Toksin Uygulamaları ve Masseter Botoksu (2024) — Türkiye KlinikleriOpen source
Book an appointment for Masseter Botox?
Schedule a complimentary consultation with Op. Dr. Hamza Gemici.
Book Now